Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 982.29 +14.31 (+1.48%) Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 Next > Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) January 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards January 24, 2024 Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Sets New 52-Week High in Tuesday Session January 23, 2024 Via Investor Brand Network Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement January 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 health care stocks off to strong starts in 2024 January 10, 2024 With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 January 05, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Records 52-Week High Wednesday Morning January 03, 2024 Via Investor Brand Network 2 gene-editing stocks reshaping hereditary disease treatments January 02, 2024 Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Via MarketBeat Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year December 11, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes December 10, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes December 10, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 biotech powerhouses poised to thrive amid sector rebound December 08, 2023 If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. Via MarketBeat Topics ETFs Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma December 07, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO December 07, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio November 30, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease November 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentation November 15, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF) November 13, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH November 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Reports Third Quarter 2023 Financial and Operating Results November 02, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema November 01, 2023 Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient... From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss October 26, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations October 25, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 October 25, 2023 EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END Via FinancialNewsMedia Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE) October 22, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC) October 21, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria October 20, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN October 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry October 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.